J&J to eliminate 900 sales-related positions

Share this article:

Johnson & Johnson will cut 900 positions at its Ortho-McNeil-Janssen Pharmaceuticals unit by the end of the second quarter.

According to Kara Russell, a J&J spokesperson, the reduction is part of an overarching corporate strategy focused on dealing with a shift in the pharmaceutical landscape—particularly with respect to the way doctors interact with drug companies.

“Physicians have really begun to voice how they would like to receive [product] information, and when and where they'd like to receive it,” said Russell.

The elimination of 900 positions does not necessarily mean that 900 employees will lose their jobs, noted Russell. Some of the positions will be eliminated through attrition and hiring freezes, she said.

The J&J move follows many other pharma restructurings and reorganizations that usually shed jobs. Increased generic competition, coupled with relatively barren pipelines, has spurred consolidation and mergers across the industry.

“We're taking into consideration what is best for our multiple stakeholders,” said Russell.

Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.